Dengvaxia: Boon for Dengue

Posted on

The recent outbreak of Dengue in Asia has brought forward the threat of mosquito bite into the spotlight again. Dengue is a kind of viral infection caused by mosquito bite, and the disease has now become a threat to about 390 million people, as these many are estimated to be infected each year. This incidence of infection in recent decades has soared and the world has been a witness to a great number of deaths globally. Asia is emerging to be the most impacted region with about 75% of the global burden of dengue.

According to World Health Organization (WHO), the number of the cases in Malaysia, Philippines, Vietnam and India has increased alarmingly, as compared to what it was two years ago. However, there is hope for its effective treatment and cure, as Sanofi Pasteur has successfully developed a vaccine after investing approximately 20 years in R&D. Sanofi Pasteur is the first company to come up with dengue vaccine named as “Dengvaxia”. According to Sanofi, they want to make the drug available to everyone, particularly to the low income countries. For this they have joined hands with a number of International Organizations like World Health Organization (WHO), United Nations Children’s Fund (UNICEF), and Red Cross.

So far, the drug has got market approval in 11 countries, including Mexico, Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore; Mexico is the one to become the first country to license it. The company is now waiting for its approval from the Indian government which may take some more time as the government has asked to conduct more trials before granting permission.

Neil Ferguson, Director of the MRC center for Outbreak Analysis and Modeling at Imperial College London, conducted a study that used the previous data to determine its effect in various settings found out that the vaccine may not work properly in areas where there is low prevalence of dengue; the WHO has thus not recommended countries to implement a national vaccination program using Dengvaxia. Companies like Sun Pharma, Takeda and Butantan Institute, Brazil are also working on dengue vaccine and we can expect a more efficacy from their products.

Insight by:
Megha Khandelwal
Associate Analyst



Infectious Disease and Vaccines Pipeline Reports

Posted on Updated on


DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports.


Infectious Diseases and Vaccines

The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a first vaccine, and even routine vaccinations, such as those for influenza can be improved in terms of safety and efficacy. Such unmet needs are driving the continued development of ID vaccines.

Get  Notified About Whats in Others Pipeline

The research work for curing Infectious disease has rapidly assumed a prioritized role within the overall scientific portfolio. The number of vaccines development underway has increased substantially for the HCV, HIV, Tuberculosis and Influenza infections.

Get notified about all the under development vaccines worldwide and the technology they are using, stage of development, their targets, mechanism of action with our Pipeline reports. The best strategic report that will not even give you the overall developing drug profiles but also therapeutic assessment and comparative analysis at every step such as monotherapy, combination, route of administration.

Pipeline Insights Reports

HCV Vaccine-Pipeline Insights, 2014 

HIV Vaccine-Pipeline Insights, 2014 

Influenza Vaccine-Pipeline Insights, 2014 

Tuberculosis Vaccine-Pipeline Insights, 2014


For further information email us at